Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix

Abstract

For Japanese patients with UCC receiving primary or adjuvant CCRT therapy, the recommended CDDP dose was determined to be 30 mg/m(2) for the weekly schedule and 75 mg/m(2) for the monthly schedule.

Concurrent chemoradiation for cervical cancer: what should we do next?

“…Therefore, there are no feasibility data for this protocol evaluated by standard DLT criteria, as Watanabe et al 6 stated in their report. Keys et al,3 in GOG-123, showed that 90% of patients were able to receive four or more courses of cisplatin.…”

“…However, these studies 2,3 did not describe the details or the number of patients who required treatment modification and/or treatment delay, especially in regard to cisplatin administration. As mentioned above, Watanabe et al 6 have now stated explicitly that more than a 7-day treatment delay constitutes a DLT. Can we not conclude that 8-14 days of delay in cisplatin administration is clinically acceptable in CCRT?…”

“…5 In contrast, 80%-90% of patients entered in the GOG studies were below 60 years of age. 2-4 Therefore, an original prospective clinical study of CCRT for Japanese patients has been encouraged to assess the feasibility and toxicity of weekly cisplatin at 40 mg/m 2 .In this issue of the International Journal of Clinical Oncology, Watanabe et al 6 report the results of a phase I study of CCRT with single-agent cisplatin in Japanese patients with cervical cancer. They designed two dose-escalation programs for weekly and monthly schedules.…”

“…In this issue of the International Journal of Clinical Oncology, Watanabe et al 6 report the results of a phase I study of CCRT with single-agent cisplatin in Japanese patients with cervical cancer. They designed two dose-escalation programs for weekly and monthly schedules.…”

Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer

“…The first concerns the feasibility of using the standard chemotherapy of weekly 40 mg/m 2 cisplatin concurrently with radiotherapy. There have been several reports that Japanese cervical cancer patients frequently experienced severe toxicities, and investigators concluded that CCRT using weekly 40 mg/m 2 cisplatin may not be feasible for Japanese patients [2,3]. The second is that there are limited data on CCRT using high-dose-rate intracavitary brachytherapy (HDR-ICBT) [4,5].…”